stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Return on assets
Replimune Group, Inc.'s return on assets over the twelve months to 30 September 2026 was −71.0%, up 0.0 percentage points from fiscal 2026 (−71.1%). Over the past ten years it has ranged from −71.1% (fiscal 2026) to −17.5% (fiscal 2017) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of −45.5% and below the Healthcare sector median of −28.8%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2026 | −71.1% | (23.45) |
| FY2025 | −47.6% | (9.55) |
| FY2024 | −38.1% | (6.58) |
| FY2023 | −31.5% | (7.96) |
| FY2022 | −23.5% | (2.70) |
| FY2021 | −20.8% | 6.29 |
| FY2020 | −27.1% | 1.00 |
| FY2019 | −28.1% | 16.69 |
| FY2018 | −44.8% | (27.27) |
| FY2017 | −17.5% | — |
Against its own ten years
Low −71.1%
High −17.5%
Ten-year median
−29.8%
Current reading's percentile
10
Return on assets against peers
| Company | Return on assets |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 46.5% |
| ZYME Zymeworks Inc. compare | 5.50% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| VIR Vir Biotechnology, Inc. compare | −17.3% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −36.3% |
| IMNM Immunome, Inc. compare | −70.2% |
| REPL Replimune Group, Inc. | −71.0% |
| VERA Vera Therapeutics, Inc. compare | −72.3% |
| Biotechnology industry median | −45.5% |
| Healthcare sector median | −28.8% |
| Market median | 0.07% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)